Engineered cleavage half-domains

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Sangamo Biosciences, Inc. patent solves the following problem:

Artificial nucleases, such as zinc finger nucleases (substitute the zinc finger domain and cleavage domains) for target cleavage in genomic DNA described. The target cleavage events can be used, for example, to induce targeted mutagenesis, induce targeted deletions of cellular DNA sequences, and facilitate targeted recombination at a predetermined chromosomal locus. See, for example, in United States Patent Publication 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; 20060063231; and International Publication WO 07/014275, the disclosures included in the reference in their entireties for all purposes.

Our analysis of this patent is as follows:

Sangamo Biosciences, Inc.’s patent US 9376689 B2 deals with Engineered cleavage half-domains.
Expressed in the engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains, and fusion proteins; and cells comprising said polynucleotides and / or fusion protein. Also described are methods of using these polypeptides and polynucleotides, for example for target cleavage in a genomic sequences.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Linear donor constructs for targeted integration

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Sangamo Biosciences, Inc. patent solves the following problem:

A great place of interest in genome biology, especially in light of the determination of the complete nucleotide sequences of a number of genomes, is the targeted integration of genomic sequences. Attempts have been made to genomic sequences in cultured cells by exploiting the natural occurrence of homologous recombination. See, for example, Capecchi (1989) Science 244: 1288-1292; US Pat. Num. 6,528,313 and 6,528,314.

Our analysis of this patent is as follows:

Sangamo Biosciences, Inc.’s patent US 9376685 B2 deals with Linear donor constructs for targeted integration.
Said here is the linear donor molecules comprising homology arms of 50-750 base pairs (eg, 50-100 base pairs) in the side of one or more sequences of interest. The donor molecules and / or compositions containing these molecules can be used in methods for targeted integration of an exogenous sequences into a specified region of interest in the genome of a cell.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method of treating pulmonary disease by administering an antibody to G-CSF

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Csl Limited patent solves the following problem:

Bibliographic details of references provided in the subject specification are listed at the end of the call.

Our analysis of this patent is as follows:

Csl Limited’s patent US 9376682 B2 deals with Method of treating pulmonary disease by administering an antibody to G-CSF.
The present invention relates generally to a method for treating or preventing or ameliorating the effects of pulmonary diseases characterized by or associated with the infiltration of neutrophils and complications arising thereof. The present invention further provides agents and pharmaceutical compositions comprising agents that inhibit the activity of G-CSF receptor, interfere with G-CSF signaling and / or to control expression of G-CSF or its receptor.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Cornell Research Foundation, Inc. patent solves the following problem:

Many autoimmune polyneuropathies arise when nerves are damaged by own immune system of the body. Symptoms of this disease include numbness, muscle weakness, limb pain, distress, sensitivity to touch and reduced tendon reflex. In general, autoimmune polyneuropathies be categories of demyelinating and axonal neuropathies.

Our analysis of this patent is as follows:

Cornell Research Foundation, Inc.’s patent US 9375473 B2 deals with Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases.
The invention relates to methods of preventing or inhibiting the onset and / or treating autoimmune demyelinating neuropathy and other autoimmune or inflammatory diseases involving macrophage infiltration.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Combination immunotherapy for the treatment of cancer

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Board Of Regents, The University Of Texas System, , Memorial Sloan-Kettering Cancer Center patent solves the following problem:

Optimal T cell activation requires contemporaneous signal through the T cell receptor and costimulatory molecules. CD28, the prototypical costimulatory molecules, on interactions with its ligands B7-1 and B7-2, plays an important role in the initial T cell moves. Sharpe et al., Nat. Rev. Immunol. 2: 203-209 (2002). CD28-mediated T cell expansion against other B7-1,2 counter receptor, cytotoxic T lymphocyte associated antigen 4 (CTLA-4), which attenuates the proliferation of recently activated T cells. Krümmel et al., J. Exp. Med. 183: 2533-2540 (1996); Leach et al, Science 271 :. 1734-1736 (1996). Temporal regulation of CD28 and CTLA-4 expression maintains a balance between moving and inhibitory signal and ensures the development of an effective immune response, while protecting against the development of autoimmunity. Blockade of inhibitory signal mediated CTLA-4 was shown to enhance T cell responses and induce tumor rejection in a number of animal models, and monoclonal antibodies to human CTLA-4 found modest success in continuing human clinical trials, including the strong absolute answers in a small subset of patients with metastatic disease. See, for example Korman et al, adv. Immunol. 90: 297-339 (2006).

Our analysis of this patent is as follows:

Board Of Regents, The University Of Texas System, , Memorial Sloan-Kettering Cancer Center’s patent US 9375475 B2 deals with Combination immunotherapy for the treatment of cancer.
ICOS agonists in combination with a blocking agent to a T cell inhibitory receptor (eg, CTLA-4, PD-1, etc.) is here shown to be useful for the treatment of tumors.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Compounds useful for inhibiting metastasis from cancer and methods using same

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Drexel University, , Alliance Discovery, Inc. patent solves the following problem:

Metastasis or metastatic disease is the spread of a disease from one organ or part to another non-adjacent organ or part. Metastatic disease is the first but not uniquely associated with the malignant tumor cells and infections (Klein, 2008, Science 321 (5897): 1785-88; Chiang Massagu, 2008, New Engl J Med 359 (26) : 2814-23).

Our analysis of this patent is as follows:

Drexel University, , Alliance Discovery, Inc.’s patent US 9375474 B2 deals with Compounds useful for inhibiting metastasis from cancer and methods using same.
The present invention includes compositions useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods to prevent or treat metastasis in a subject diagnosed with cancer, which method comprises administering to a subject in need thereof an effective amount of a pharmaceutical formulation comprising eleven at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine enemies.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Light sensor with chemically resistant and robust reflector stack

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Newport Fab, Llc patent solves the following problem:

The present application claims the benefit of priority to a provisional patent application entitled Light sensor with chemical substances Resistant and strong reflector stack, Ser. No. 62 / 045,706 filed on Aug. 4, 2014. The disclosure of this provisional application is incorporated in full by reference into the present application.

Our analysis of this patent is as follows:

Newport Fab, Llc’s patent US 9377350 B2 deals with Light sensor with chemically resistant and robust reflector stack.
A light sensor has a chemical resistant and strong reflector neat disclosed. The reflector assembly is formed on a substrate, and includes an extrusion layer, a patterned reflector layer upon layer extrusion, and a smoothing layer over the patterned reflector layer. Followed reflector layer has a substantially flat surface. A conformal passivation layer consists of reflector stacks. One interesting layer located over the reflector assembly and separated from the reflector stacks. The fascinating layer supported the vias on the substrate. Interestingly, the layer having at least one resistor, where a resistance to at least one resistor varies in response to the light absorbed by the fascinating layer. The vias wanted by landing pads on the substrate.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Ensuring availability of data in a set being uncorrelated over time

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Amazon Technologies, Inc. patent solves the following problem:

Computing resource monitoring system evolved and continue to evolve to keep up with the demands of the organizations that use them. Many organizations, for example, the computing resource usage monitoring system for, among other reasons, evaluate one or more metrics associated with the resources and applications that organizations to be used to support their business. Despite their many advantages, many modern computing resources monitoring system prone to data corruption or defects which resulted in the decrease in the data and potential data loss. For example, if a storage node in a computing resource monitoring system is damaged or rendered unavailable, the data stored in order to be unavailable and, without extra, will be lost. In the meantime, many modern computing resources monitoring system using a horizontal partition to store one or more metrics that, if lost, may result in any metrics that resides within the partition unavailable for all reads and writes to any point in time. Moreover, these modern computing resources monitoring system to be configured to monitor one or more services to be automatically scaled according to customer and system requirements. This, in turn, could exacerbate the effects of any unavailability metrics associated with the resources and applications that are supported by the monitoring service computing resources. Adequately addressing these issues, together with provisioning additional resources to the full data redundancy in the event one or more unavailable storage nodes, presenting additional cost to organizations that rely on Computing resources monitoring systems and computing resources to the service provider to provide the computing resource monitoring service to its customers.

Our analysis of this patent is as follows:

Amazon Technologies, Inc.’s patent US 9378230 B1 deals with Ensuring availability of data in a set being uncorrelated over time.
A Computing resource monitoring service receives an executable command to redundantly store a metric computation of the resources provided by the customer to a computing resource service provider. The executable command may contain a hash key and a hash value for the metric. Based on the hash key included in the executable command, the Computing resource monitoring service can choose one or more data zones, each of the zones of data that contains one or more of the storage nodes for storing metrics. Computing resources monitoring service can be configured to obtain a schedule of storage nodes from the zones of the data to determine the active storage nodes based at least in part to the hash key. Therefore, the Computing resource monitoring service to identify a storage node from one or more active nodes based at least in part on the hash key and store the metric identified nodes boil.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method and apparatus for differentiated access control

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Blackberry Limited patent solves the following problem:

Computing devices, including mobile devices such as personal digital assistants, smart phones, mobile phones, laptops, among others, as well as desktop or other computing device capable of running many applications at one time. For security purposes, a user or an IT policy for user may dictate that the lock computer access devices to applications running after a period of inactivity. For example, if the user has not touched the computing device for 2 minutes, all the applications in devices to Lock. The user then needs to enter a password before using any application on the device.

Our analysis of this patent is as follows:

Blackberry Limited’s patent US 9378394 B2 deals with Method and apparatus for differentiated access control.
A method for differentiated access control in a computing device that has a connection with a second device, the method to check whether a timer to expire in the second device or a connection lost in the second dodge; and control at least one of the plurality of subsets of applications from launching or done if the timer has expired on the second device connection or lost the second device.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Purposeful computing

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Advanced Elemental Technologies, Inc. patent solves the following problem:

Aspects of the disclosure relates in general to computing architecture. Aspects include a device, a method and system configured to facilitate the user's purpose in a Computing architecture.

Our analysis of this patent is as follows:

Advanced Elemental Technologies, Inc.’s patent US 9378065 B2 deals with Purposeful computing.
A system, method, and computer-readable storage medium configured to facilitate the end user in a Computing architecture.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.